Stock Ratings / Health Care / BVS / earnings

DRTS (33) PRCT (48) AORT (54) TNDM (35) ⌘ Pro Terminal →

Bioventus Inc. (Class A) (BVS) Next Earnings Date & Expected ±8.6% Move

$14.87 +1.50% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Bioventus Inc. (Class A) (BVS) carries a Roarable Rating of C+ (Hold) with 66/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

ROARABLE C+ • HOLD / WATCH Cap $1.25B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERHOLD / WATCH • C+

2-of-3 JEV AI Jury Bullish

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C · Rk B

Each axis scored 0–20

12M PRICE TARGET CONE+3.6% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for BVS)Realized 20D OHLCV Swing Band: ±8.6%

NEXT EST. WINDOW: Dec 30, 2026 (~58 DAYS)

Historical OHLCV Volatility ±8.6% Swing Band

±$1.28 Expected Swing

MODEL EARNINGS SETUP GAUGE

BVS Quantitative Pre-Earnings Setup: 66/100

Trailing EPS: $0.27 • YoY Revenue Growth: -0.9%

Model Bullish Setup (66/100)Model Risk Weight (34/100)

Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).

LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

Period	Filed	Revenue	Net Profit	Free Cash Flow	Gross Margin
FY 2025	2025-12-31	$568.1M	$22.7M	$72.1M	68.3%
FY 2024	2024-12-31	$573.3M	-$36.1M	$37.8M	67.7%
FY 2023	2023-12-31	$512.3M	-$156.2M	$15.3M	68.3%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher + Options & Swing Structure Desk

Whale Flow & Momentum Playbook: Evaluating BVS & AI Leaders Without Chasing Tops

✓Institutional whale strikes & implied earnings move audit on BVS
✓How disciplined traders manage risk using pre-published trigger & invalidation levels
✓Includes nightly RQD rating-change & forensic signal email alerts on tracked leaders

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

BVS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +50.66%⚡ TESTING RESISTANCE

2026-10-30O $14.84H $14.87L $13.32C $14.87VOL 666.7K

RES: $15.36SUP: $12.85SMA50: $13.70SMA200: $10.90

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

BVS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 BVS Butterfly Map → + Track BVS →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

39.0%/yr Implied 5Y Growth

vs. -0.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on BVS today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for BVS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for BVS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BVS)

Health Care Rank #129 of 1016 ⚔️ DRTS vs BVS Full Matrix →

1. Head-to-Head Health Care Peer Comparison (BVS vs. DRTS, PRCT, AORT, TNDM)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Bioventus Inc. (Class A) (BVS) ranks #129 by composite RQD confidence (66/100, grade C+) and #332 by equity capitalization ($1.25B). Within this direct 5-issuer industry benchmark cohort, BVS leads on earnings valuation at 55.0x trailing P/E, while BVS leads on capital efficiency and profitability with 10.4% ROIC and 68.3% gross margin. BVS currently leads its immediate peer cohort in composite quantitative strength at 66/100 (C+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
BVS ACTIVE Bioventus Inc. (Class A)	C+	66/100	55.0x	68.3%	10.4%	+1.50%	$1.25B	Benchmark Subject
DRTS Alpha Tau Medical Ltd.	E	33/100	—	—	-35.0%	-0.90%	$1.22B	/drts-vs-bvs →
PRCT PROCEPT BioRobotics Corporation	D	48/100	—	63.7%	-35.0%	+0.50%	$1.16B	/prct-vs-bvs →
AORT Artivion Inc.	D+	54/100	117.0x	64.4%	4.5%	+2.27%	$1.14B	/aort-vs-bvs →
TNDM Tandem Diabetes Care Inc.	D-	35/100	—	53.8%	-35.0%	+0.56%	$1.38B	/tndm-vs-bvs →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001665988

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Bioventus Inc. (Class A) (BVS) reported GAAP revenue of $568.1M (-0.9% vs. FY2024 revenue of $573.3M , and +10.9% cumulative change since FY2023) , GAAP net income of $22.7M, operating cash flow of $74.7M, and free cash flow of $72.1M (+90.8% YoY). On the balance sheet, BVS closed FY2025 with $683.6M in total assets against $279.0M in total debt (Altman Z-Score: 2.25, Piotroski F-Score: 7/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$568.1M	$22.7M	$74.7M	$72.1M	$683.6M	$279.0M
FY2024 (FY)	2024-12-31	$573.3M	-$36.1M	$38.8M	$37.8M	$728.0M	$308.3M
FY2023 (FY)	2023-12-31	$512.3M	-$156.2M	$15.3M	$15.3M	—	—

3. BVS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is BVS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Bioventus Inc. (Class A) (NASDAQ: BVS) is rated C+ (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 66/100 at a spot price of $14.87 (+1.50% 1D, market cap $1.25B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 12/20. Across 1016 tracked Health Care issuers, BVS ranks #129 in composite RQD confidence.

How does BVS compare to DRTS and PRCT in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), BVS carries a Roarable C+ (66/100 RQD), trailing P/E of 55.0x, gross margin of 68.3%, and ROIC of 10.4%. By comparison, DRTS (Alpha Tau Medical Ltd.) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $1.22B) and PRCT (PROCEPT BioRobotics Corporation) posts a D grade (48/100 RQD, P/E N/A, ROIC -35.0%, cap $1.16B). Among the 5-stock peer group, BVS leads on earnings multiple (55.0x) while BVS leads on capital efficiency (10.4% ROIC).

What are the biggest fundamental strengths and SEC risk factors for BVS?

Per BVS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001665988), Bioventus Inc. (Class A) generated $568.1M in revenue (-0.9% YoY), $22.7M in net income, and $72.1M in free cash flow against $683.6M in total assets and $279.0M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Priced at 55x earnings—high expectations leave less room for a lukewarm quarter.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is BVS trading relative to its 50-day, 200-day, and 52-week technical levels?

BVS last traded at $14.87 (+1.50% on volume of 444,933 shares), positioning the stock +8.54% above its 50-day simple moving average ($13.70) and +36.42% above its 200-day simple moving average ($10.90). Across its 52-week range of $6.47 to $15.89, BVS sits at the 89.2% percentile with a 14-day RSI of 43.9 (NEUTRAL RANGE) and an implied next-earnings move of ±8.6% ($13.59 to $16.15).

BVS Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

When is BVS's next earnings date?

Based on SEC filing cadence, Bioventus Inc. (Class A) (BVS)'s next quarterly reporting window is estimated around Dec 30, 2026.

How much is BVS stock expected to move on earnings?

Volatility modeling currently projects a ±8.6% event move for BVS, spanning a range between $13.59 and $16.15.

Direct Sub-Reports: BVS RQD Cockpit BVS 12M Forecast BVS Earnings & Move BVS Dividends & DRIP BVS Insiders & 13F BVS Whale Options BVS Profit Sankey BVS News & Why